-
公开(公告)号：US20100105877A1
公开(公告)日：2010-04-29
申请号：US12523050
申请日：2008-01-04
Applicant: Dae Hae Song , Chang Ki Lim , Tae Hun Song , Young Hoon Kim , Se Chang Kwon , Gwan Sun Lee , Sung Youb Jung , In Young Choi
Inventor： Dae Hae Song , Chang Ki Lim , Tae Hun Song , Young Hoon Kim , Se Chang Kwon , Gwan Sun Lee , Sung Youb Jung , In Young Choi
IPC: C07K16/00
CPC classification number: C07K14/57563 , A61K38/00 , A61K47/6835 , C07K14/605
Abstract: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.
Abstract translation: 本发明涉及具有改善的功效和稳定性的体内持续时间的促胰岛素肽缀合物，其包含彼此共价连接的促胰岛素肽，非肽聚合物和免疫球蛋白Fc区，并且使用它们 。 本发明的促胰岛素肽缀合物具有保持较高的体内活性，并且血液半衰期显着增加，因此可以理想地用于开发各种肽药物的长效制剂。
-
32.发明授权Modified human granulocyte-colony stimulating factor and process for producing same 有权改良人粒细胞集落刺激因子及其制备方法公开(公告)号：US07704709B2
公开(公告)日：2010-04-27
申请号：US11975541
申请日：2007-10-19
Applicant: Se-Chang Kwon , Sung-Youb Jung , Sung-Min Bae , Gwan-Sun Lee
Inventor： Se-Chang Kwon , Sung-Youb Jung , Sung-Min Bae , Gwan-Sun Lee
IPC: C07K14/00 , C07K14/435 , C07K14/46 , C07K14/47 , C07K14/475 , C07K14/52 , C07K14/53 , C07K14/535 , C12N15/09 , C12N15/11 , C12N15/12 , C12N15/19 , C12N15/27 , C12N15/63 , C12N15/70 , C12N15/72
CPC classification number: C07K14/535 , C07K2319/034 , C07K2319/75 , C12N15/625 , C12N15/70
Abstract: A modified human granulocyte-colony stimulating factor (hG-CSF) is produced by culturing a microorganism transformed with an expression vector comprising a gene encoding a modified hG-CSF to produce and secrete the modified hG-CSF to periplasm, said modified hG-CSF being obtained by replacing at least one of the 1st, 2nd, 3rd and 17th amino acids of wild-type hG-CSF (SEQ ID NO: 2) with other amino acid.
Abstract translation: 通过培养用包含编码修饰的hG-CSF的基因的表达载体转化的微生物来产生修饰的人粒细胞集落刺激因子（hG-CSF），以产生和分泌经修饰的hG-CSF至周质，所述修饰的hG-CSF 通过将野生型hG-CSF（SEQ ID NO：2）的第1，第2，第3和第17氨基酸中的至少一个替换为其他氨基酸而获得。
-
33.发明授权Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same 有权用于人类干扰素α的表达和分泌载体以及通过使用它们产生人干扰素α的方法公开(公告)号：US07052867B2
公开(公告)日：2006-05-30
申请号：US10182040
申请日：2001-01-19
Applicant: Se-Chang Kwon , Sung-Youb Jung , Ki-Doo Choi , Cha-Soon Kim , Sung-Min Bae , Gwan-Sun Lee
Inventor： Se-Chang Kwon , Sung-Youb Jung , Ki-Doo Choi , Cha-Soon Kim , Sung-Min Bae , Gwan-Sun Lee
CPC classification number: C07K14/245 , C07K14/56 , C07K2319/02 , C12N15/70
Abstract: Disclosed in this invention are an expression vector for the secretive production of human interferon alpha (hIFNα) comprising a polynucleotide encoding a modified E. coli thermostable enterotoxin II signal sequence and a polynucleotide encoding hIFNα ligated to the 3′-end thereof; a microorganism transformed with the expression vector; and a process for secretively producing human interferon by culturing the microorganism, the process being capable of secreting a soluble form of active hIFNα, which does not contain an additional methionine residue at its N-terminal, into the periplasm of an E. coli cell.
Abstract translation: 在本发明中公开了用于分泌生产人干扰素α（hIFNα）的表达载体，其包含编码修饰的大肠杆菌热稳定性肠毒素II信号序列的多核苷酸和编码连接于其3'端的hIFNα的多核苷酸; 用表达载体转化的微生物; 以及通过培养微生物分泌生产人类干扰素的方法，该方法能够将在其N-末端不含另外的甲硫氨酸残基的可溶形式的活性hIFNα分泌到大肠杆菌细胞的周质中。
-
34.发明授权公开(公告)号：US08846874B2
公开(公告)日：2014-09-30
申请号：US10535341
申请日：2004-11-13
Applicant: Sung Youb Jung , Jin Sun Kim , Geun Hee Yang , Se Chang Kwon , Gwan Sun Lee
Inventor： Sung Youb Jung , Jin Sun Kim , Geun Hee Yang , Se Chang Kwon , Gwan Sun Lee
IPC: C07K16/00 , A61K39/40 , C07K14/505 , A61K47/48 , C07K19/00 , C07K14/56 , C07K14/535 , C07K14/61 , C07K16/46 , C07K1/00
CPC classification number: A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
Abstract translation: 公开了可用作药物载体的IgG Fc片段。 此外，本发明公开了表达IgG Fc片段的重组载体，用重组载体转化的转化体，以及制备IgG Fc片段的方法，包括培养转化体。 当缀合到某种药物时，IgG Fc片段改善了药物作用的体内持续时间并使药物的体内活性降低最小化。
-
公开(公告)号：US08822650B2
公开(公告)日：2014-09-02
申请号：US13087593
申请日：2011-04-15
Applicant: Sung Youb Jung , Jin Sun Kim , Young Jin Park , Ki-Doo Choi , Se Chang Kwon , Gwan Sun Lee
Inventor： Sung Youb Jung , Jin Sun Kim , Young Jin Park , Ki-Doo Choi , Se Chang Kwon , Gwan Sun Lee
IPC: C12P21/08 , C07K16/00 , C07K19/00 , A61K47/48 , C07K16/46 , C07K14/505 , C07K14/56 , C07K14/61 , C07K14/535
CPC classification number: A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
Abstract translation: 公开了包含编码大肠杆菌来源的信号序列的核苷酸序列和编码免疫球蛋白恒定区的核苷酸序列的重组表达载体和用表达载体转化的转化体。 此外，公开了通过培养转化体并以水溶性形式表达免疫球蛋白恒定区来大规模生产免疫球蛋白恒定区的方法。
-
Patent Agency Ranking
36.发明授权Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein 失效制备用于其中的卡培他滨和β-异头物富含三烷基碳酸酯化合物的方法公开(公告)号：US08097706B2
公开(公告)日：2012-01-17
申请号：US12742367
申请日：2008-11-07
Applicant: Jaeheon Lee , Gha-Seung Park , Weon Ki Yang , Jin Hee Kim , Cheol Hyun Park , Yong-Hoon An , Yoon Ju Lee , Young-Kil Chang , Gwan Sun Lee
Inventor： Jaeheon Lee , Gha-Seung Park , Weon Ki Yang , Jin Hee Kim , Cheol Hyun Park , Yong-Hoon An , Yoon Ju Lee , Young-Kil Chang , Gwan Sun Lee
CPC classification number: C07D405/04 , C07H1/00 , C07H19/06 , Y02P20/55
Abstract: The present invention relates to a method for preparing capecitabine and a method for preparing a β-anomer-rich trialkyl carbonate compound used therein, and a highly pure capecitabine can be efficiently prepared with a high yield by the method of the present invention using the β-anomer-rich trialkyl carbonate compound as an intermediate.
Abstract translation: 本发明涉及一种制备卡培他滨的方法和一种制备其中使用的富含甘油的三烷基碳酸酯化合物的方法，可以通过本发明的方法以高产率有效地制备高纯度的卡培他滨 富马酸三烷基碳酸酯化合物作为中间体。
-
公开(公告)号：US20110245472A1
公开(公告)日：2011-10-06
申请号：US13087593
申请日：2011-04-15
Applicant: Sung Youb JUNG , Jin Sun KIM , Young Jin PARK , Ki-Doo CHOI , Se Chang KWON , Gwan Sun LEE
Inventor： Sung Youb JUNG , Jin Sun KIM , Young Jin PARK , Ki-Doo CHOI , Se Chang KWON , Gwan Sun LEE
CPC classification number: A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
Abstract translation: 公开了包含编码大肠杆菌来源的信号序列的核苷酸序列和编码免疫球蛋白恒定区的核苷酸序列的重组表达载体和用表达载体转化的转化体。 此外，公开了通过培养转化体并以水溶性形式表达免疫球蛋白恒定区来大规模生产免疫球蛋白恒定区的方法。
-
公开(公告)号：US08029789B2
公开(公告)日：2011-10-04
申请号：US10535312
申请日：2004-11-13
Applicant: Sung Youb Jung , Jin Sun Kim , Young Jin Park , Ki-Doo Choi , Se Chang Kwon , Gwan Sun Lee
Inventor： Sung Youb Jung , Jin Sun Kim , Young Jin Park , Ki-Doo Choi , Se Chang Kwon , Gwan Sun Lee
CPC classification number: A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
Abstract translation: 公开了包含编码大肠杆菌来源的信号序列的核苷酸序列和编码免疫球蛋白恒定区的核苷酸序列的重组表达载体和用表达载体转化的转化体。 此外，公开了通过培养转化体并以水溶性形式表达免疫球蛋白恒定区来大规模生产免疫球蛋白恒定区的方法。
-
39.发明申请METHOD FOR PREPARING (3S,4S)-4-((R)-2-(BENZYLOXY)TRIDECYL)-3-HEXYL-2-OXETANONE AND NOVEL INTERMEDIATE USED THEREFOR 失效制备（3S，4S）-4 - （（R）-2-（苄氧基）吡啶-3-基）-3-甲基-2-氧代西他酮的方法及其所用的新型中间体公开(公告)号：US20110178330A1
公开(公告)日：2011-07-21
申请号：US13120561
申请日：2009-10-30
Applicant: Sang Min Yun , Dong Jin Hong , Weon Ki Yang , Jae Ho Yoo , Ji Sook Kim , Moon Sub Lee , Han Kyong Kim , Eun Jung Lim , Young Ho Moon , Young-Kil Chang , Gwan Sun Lee
Inventor： Sang Min Yun , Dong Jin Hong , Weon Ki Yang , Jae Ho Yoo , Ji Sook Kim , Moon Sub Lee , Han Kyong Kim , Eun Jung Lim , Young Ho Moon , Young-Kil Chang , Gwan Sun Lee
IPC: C07C53/00
CPC classification number: C07D305/12 , C07C51/09 , C07C51/353 , C07C59/29 , C07C59/72
Abstract: The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.
Abstract translation: 本发明涉及使用（2S，4S）-4 - （（R）-2-（苄氧基）十三烷基）-3-己基-2-氧杂环丁酮的金属盐制备高纯度 3S，5R）-2-己基-3,5-二羟基十六烷酸作为中间体。
-
40.发明申请CRYSTALLINE S-OMEPRAZOLE STRONTIUM HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 有权水溶性S-奥美拉唑水合物，其制备方法和含有其的药物组合物公开(公告)号：US20110046383A1
公开(公告)日：2011-02-24
申请号：US12914032
申请日：2010-10-28
Applicant: Tae Hee HA , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
Inventor： Tae Hee HA , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
IPC: C07D401/12
CPC classification number: C07D401/12
Abstract: Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
Abstract translation: 公开了一种用于预防或治疗胃酸相关疾病的结晶性S-奥美拉唑锶水合物，其具有高光学纯度，耐久性，溶解性和不吸湿性，其制备方法和含有其的药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
103
records
(took 0.027 seconds)
